Dabrafenib, as a Novel Insight into Drug Repositioning Against Secretory Group IIa Phospholipase A2
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Byeongjin | - |
dc.contributor.author | Kim, Jaehong | - |
dc.contributor.author | Bae, Jong-Sup | - |
dc.date.available | 2020-02-28T06:44:03Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1811-7775 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9745 | - |
dc.description.abstract | The screening of bioactive compound libraries can be an effective approach for repositioning FDA-approved drugs or discovering new treatments for human diseases. The expression of secretory group IIa phospholipase A2 (sPLA2-IIa) is enhanced by development of inflammatory disorders. In this study, sPLA2-IIa expression was induced in the lipopolysaccharide (LPS)-stimulated Human Umbilical Vein Endothelial Cells (HUVECs) and mice to evaluate the effect of dabrafenib. This study illustrates drug repositioning with dabrafenib (DAB) for the modulation of sPLA2-IIa expression and activity. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Results showed that dabrafenib remarkably suppressed the LPS-mediated protein expression and activity of sPLA2-IIa via inhibition of phosphorylation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. These results demonstrated that dabrafenib might play an important role in the modulation of sPLA2-IIa expression and activity in response to the inflammatory diseases. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET | - |
dc.relation.isPartOf | International Journal of Pharmacology | - |
dc.subject | SELECTIVE INHIBITOR | - |
dc.subject | GENE-EXPRESSION | - |
dc.subject | EXISTING DRUGS | - |
dc.subject | A(2) ENZYMES | - |
dc.subject | IN-VITRO | - |
dc.subject | PROTEIN | - |
dc.subject | SUPERFAMILY | - |
dc.subject | DISCOVERY | - |
dc.subject | CELLS | - |
dc.title | Dabrafenib, as a Novel Insight into Drug Repositioning Against Secretory Group IIa Phospholipase A2 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000380604400015 | - |
dc.identifier.doi | 10.3923/ijp.2016.415.421 | - |
dc.identifier.bibliographicCitation | International Journal of Pharmacology, v.12, no.4, pp.415 - 421 | - |
dc.identifier.scopusid | 2-s2.0-84963746827 | - |
dc.citation.endPage | 421 | - |
dc.citation.startPage | 415 | - |
dc.citation.title | International Journal of Pharmacology | - |
dc.citation.volume | 12 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Kim, Jaehong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Dabrafenib | - |
dc.subject.keywordAuthor | HUVECs | - |
dc.subject.keywordAuthor | sPLA2-IIa | - |
dc.subject.keywordAuthor | inflammation | - |
dc.subject.keywordAuthor | mice | - |
dc.subject.keywordAuthor | drug repositioning | - |
dc.subject.keywordPlus | SELECTIVE INHIBITOR | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | EXISTING DRUGS | - |
dc.subject.keywordPlus | A(2) ENZYMES | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | SUPERFAMILY | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | CELLS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.